The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic pathological and clinical factors associated with overall survival in metastatic melanoma undergoing anti PD-1 treatment.
 
Kim Koczka
No Relationships to Disclose
 
Rodrigo Rigo
No Relationships to Disclose
 
Aleksi Suo
No Relationships to Disclose
 
Mohammad Asad
No Relationships to Disclose
 
Edwin Wang
No Relationships to Disclose
 
Eugene Batuyong
Stock and Other Ownership Interests - Abeona Therapeutics; Acasti Pharma; Acorda Therapeutics; Actinium Pharmaceuticals; Adamis; Adaptimmune; Advaxis; Agenus; AgeX Therapeutics; AIM ImmunoTech; Akari Therapeutics; AlphaProTech; Altimmune; Amarin Corporation; Ampio Pharmaceuticals; Anavex Life Sciences; Aphria; Applied DNA Sciences; Applied DNA Sciences; Astrotech; Aurinia Pharmaceuticals; Auris; Aurora Cannabis; Avadel Pharmaceuticals; Aytu BioScience; Bausch Health Companies; Bellicum Pharmaceuticals; Bio-Key International; Biocept; BioCryst; BioNano Genomics; Brainstorm Cell Therapeutics; Caladrius Biosciences; Capricor Therapeutics; Cassava Sciences; Catalyst Biosciences; Celldex; Cellectar; Celsion; Citius Pharmaceuticals; Clovis Oncology; Co-Diagnostics; Correvio Pharma; Corvus Pharmaceuticals; CTI Biopharma Corp; Cymabay Therapeutics; Dare Bioscience; DelMar Pharmaceuticals; Diffusion Pharmaceuticals; Diffusion Pharmaceuticals; Durect Corporation; Enzo Biochem; Epizyme; Exelixis; Genmab; Geron; Heat Biologics; iBio; Idera; IMV; Inovio Pharmaceuticals; Karyopharm Therapeutics; Leap Therapeutics; Lineagen; Lipocine; Mallinckrodt; Medicinova; MEI Pharma; Mesoblast; Milestone Pharmaceuticals; miRagen; Moleculin Biotech; NanoViricides; Newlink Genetics; Novavax; Onconova Therapeutics; OPKO Health; Phio Pharmaceuticals; Ritter Pharmaceuticals; Rockwell Medical; Sorrento Therapeutics; Spectrum Pharmaceuticals; T2 Biosystems; Tilray; Tonix Pharmaceuticals; Trovagene; Vaxart; VBI Vaccines; Zomedica; Zynerba
 
Tina Cheng
No Relationships to Disclose